EUCTR2016-001600-40-ES进行中（未招募）1 期
Phase II randomized trial of DNX-2401 oncolytic adenovirus added to standard of care for newly diagnosed glioblastoma
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients willing and able to give informed consent.
- •2. Patient must be, in the investigator opinion, able to comply with all the protocol procedures.
- •3. Age over 18
- •4. Negative pregnant test in case of fertile women*
- •5. Patients with suspected diagnosis of Glioblastoma based on MRI,
- •5. The tumor should be considered candidate to resection surgery by the investigator criteria or being less than 4cm in bigger diameter if the tumor is considered unresectable or the patient is unwilling to have resection surgery.
- •6. A diagnosis of High Grade Glioma should be confirmed during surgical procedure.
- •7. Karnofsky Performance Status = 60 before inclusion Or could use candidate to resection surgery in number 5 to select cases with good enough situation and eliminate this criterium, preoperative situation in newly diagnosed can be tricky as sometimes a deficit at presentation of the disease can improve.
- •8. Must have adequate renal, bone marrow and liver function.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 12
排除标准
- •1.Severe infections or intercurrent medical conditions including, but not limited to, severe renal, hepatic, heart or bone marrow failure, that, on investigator´s criteria, do not allow the inclusion. Patients must be afebrile at baseline [i.e., < 38 degrees (C )].
- •2.Previous treatment for the suspected glioblastoma with radiotherapy, chemotherapy, or immunotherapy. Previous partial resection is not an exclusion criterium.
- •3.Subjects with immunodeficiency, autoimmune conditions or active hepatitis.
- •4.Any medical or psychological condition that might interfere with the subject's ability to participate or give informed consent or would compromise the patient’s ability to tolerate therapy or any disease that will obscure toxicity or dangerously alter drug metabolism.
- •5.Current diagnosis of other cancer except in situ cervical cancer, basal or squamous cell carcinoma of the skin. Patients with a history of another cancer remain eligible if they are cancer free for at least three years.
- •6.Pregnant or breast-feeding females will be excluded, due to the risk for the fetal development of a recombinant virus containing genes related to cellular growth and differentiation.
- •7.Severe bone marrow hypoplasia.
- •8.AST and/or ALT > 4 times over upper normal laboratory level.
- •9.Neutrophils < 1.5 x 109/L
- •10.Thrombocytes = 100 x 109/L
- •11.Hemoglobin < 9g/dl
- •12.If final pathology diagnose of a patient would fail to confirm the suspected diagnosis of glioblastoma or any of its variants (like gliosarcoma, giant-cell glioblastoma, or any other), that patient would follow the procedures of the trial and would be counted for toxicity analysis, but not for survival analysis.
- •13.Patients with Li-Fraumini Syndrome or with a known germ line deficit in the retinoblastoma gene or its related pathways.
- •14.Biologic/immunotherapy (e.g., IL-2, IL-12, interferon) within 4 weeks of DNX-2401 administration.
- •15.Vaccination of any kind within 30 days prior to DNX-2401 administration.
- •16. Inability to undergo MRI examination for any reason.
研究者
相似试验
招募中
不适用
The trial of neoadjuvant nivolumab, docetaxel, cisplatin therapy followed by surgery and radiation therapy for resectable high grade salivary gland carcinomaKCT0007702Samsung Medical Center50
进行中（未招募）
1 期
Treatment of no squamous non small cell lung cancero squamous non small cell lungMedDRA version: 18.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-000475-27-FRCHU de Limoges59
进行中（未招募）
不适用
A phase II clinical trial on the combination of dabrafenib and trametinib for BRAF-inhibitor pretreated patients with advanced BRAF V600 mutant melanomaadvanced BRAF V600 mutant melanomaMedDRA version: 16.1Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: HLTClassification code 10027156Term: Skin melanomas (excl ocular)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10066600Term: Melanoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10027480Term: Metastatic malignant melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-004966-33-BEZ Brussel
尚未招募
2 期
To study the effect of Deuterium depleted water in patients receiving neoadjuvant chemotherapy (NACT) for triple negative (TNBC) or HER2 positive breast cancerCTRI/2024/06/068676Tata Memorial Centre
进行中（未招募）
2 期
Phase IIa study (doctor-led trial) for the efficacy and safety of SJP-0008 in central retinal artery occlusiocentral retinal artery occlusionJPRN-jRCT2021190013akazawa Toru20